ClinicalTrials.gg
Not yet recruitingNCT07865390Updated Oct 15, 2026

Patient-Reported Outcomes Dashboard With Goal Setting to Support Shared Decision-Making in Inflammatory Arthritis

An interventional study of Patient-Reported Outcomes Dashboard With Goal Setting in Arthritis, Psoriatic (PsA) and Arthritis, Rheumatoid (RA), sponsored by Northwestern University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Northwestern University · Not applicable, Interventional, and Health services research

How we know

Updated Oct 15, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Arthritis, Psoriatic with a site in United States — 30 open to participants now, 60 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Planned enrollment
98th of 159
160 · median 228
Started
2027
the only one that year
No phase
20 of 194
3 open now
Primary completion
2027-12
later than 37 of 59 live
Registered
193rd of 194
by date

Among the 194 studies in Arthritis, Psoriatic with a site in United States, this one is the 98th largest by planned enrollment of the 159 interventional ones that give a count, is the only one that started in 2027, is one of 20 with no phase, reaches primary completion later than 37 of the 59 other live ones, and was the 193rd registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

30 of the 194 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether showing patient-reported symptoms and personal treatment goals to rheumatology clinicians on a dashboard in the electronic health record improves shared decision-making for adults with rheumatoid arthritis or psoriatic arthritis.

The main questions it aims to answer are:

  • Do patients whose clinicians use the dashboard report more shared decision-making during their rheumatology visits than patients who receive usual care?
  • Do patients in the dashboard group report greater progress toward their personal goals and more confidence in managing their symptoms after 6 months?

Researchers will compare the dashboard group to a usual care group to see if the dashboard improves shared decision-making, goal attainment, and self-efficacy.

Participants will:

  • Complete a routine symptom questionnaire before their rheumatology visits, as all clinic patients do
  • Choose personal treatment goals and rate their progress toward those goals 6 months later
  • Complete short surveys before and after two rheumatology visits about 6 months apart

Participants in the dashboard group will also complete questionnaires in the patient portal about pain, fatigue, physical function, sleep, and morning stiffness before each visit. Their answers and goals will be shown to their clinician on a dashboard to guide the conversation during the visit.

03

Conditions studied

  • Arthritis, Psoriatic (PsA)
  • Arthritis, Rheumatoid (RA)

Keywords

  • Patient Reported Outcome Measures
  • Shared Decision Making
  • PROMIS
  • Goal Attainment Scaling
  • Electronic Health Records
  • Clinical Dashboard
  • Rheumatology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of rheumatoid arthritis or psoriatic arthritis
  • Receiving care at a Northwestern Medicine rheumatology clinic, with an upcoming rheumatology visit
  • Active patient portal (MyChart) account
  • Able to read and complete questionnaires in English
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Unable to provide
  • Unable to complete study questionnaires in English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    PRO Dashboard With Goal Setting

    Before each of two routine rheumatology visits approximately 6 months apart, participants complete the RAPID3 (standard of care for all clinic patients) plus an additional questionnaire series in the patient portal: selection of personal treatment goals, a morning stiffness question, and four PROMIS computer adaptive tests (Pain Interference, Fatigue, Physical Function, and Sleep Disturbance). Responses and goals are displayed to the treating clinician on a dashboard in the electronic health record for use during the visit.

    Other: Patient-Reported Outcomes Dashboard With Goal Setting

  • No intervention
    Usual Care

    Participants receive usual rheumatology care. They do not receive the additional questionnaire series, and no study dashboard is displayed to the clinician. For outcome assessment only, participants select personal goals and rate goal attainment in study surveys that are not shared with the clinician.

Interventions

  • OtherPatient-Reported Outcomes Dashboard With Goal Setting

    A clinician-facing dashboard embedded in the Epic electronic health record that displays the participant's PROMIS computer adaptive test (CAT) scores (PROMIS Pain Interference, PROMIS Fatigue, PROMIS Physical Function, PROMIS Sleep Disturbance), morning stiffness, and self-selected treatment goals collected through the patient portal before the visit. Clinicians receive training on using the dashboard to support shared decision-making and goal-directed care during the visit.

06

What researchers measure

Primary outcomes

  1. Shared Decision-Making

    CollaboRATE is a 3-item patient-reported measure of shared decision-making during a clinical encounter. Each item is rated from 0 (no effort was made) to 9 (every effort was made). The score is the mean of the three items (range 0 to 9); higher scores indicate more shared decision-making.

    Time frame: Within 48 hours after the second study visit (approximately 6 months after enrollment)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.

Of 67 non-industry interventional studies with no phase under Arthritis, Psoriatic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 43. This study's planned 11 months is below that.

Counting every sponsor, half of 72 studies reached it within 31 months; a quarter within 13 and three quarters within 44.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Jan 2027, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2026
First posted
Oct 8, 2026
StartEst.
Jan 1, 2027was Nov 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Feb 29, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 16, 2026→Jan 1, 2027
Oct 15, 2026
Registered
First appeared on the registry
Oct 8, 2026
Show all 2 updates
  1. Oct 15, 2026
    Start date Nov 16, 2026→Jan 1, 2027
  2. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07865390
Responsible party
Maja Kuharic (Assistant Professor, Northwestern University) — Principal investigator
First posted
Oct 8, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

MAJA KUHARIC, Msc, PhD
Contact
maja.kuharic@northwestern.edu
9045547009

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion